Filing Details

Accession Number:
0001209191-14-062640
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-10-09 16:13:44
Reporting Period:
2014-10-07
Filing Date:
2014-10-09
Accepted Time:
2014-10-09 16:13:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1610876 Jeffrey Chodakewitz C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp Gmda, Cmo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-10-07 3,436 $73.51 12,936 No 4 M Direct
Common Stock Disposition 2014-10-07 902 $103.64 12,034 No 4 S Direct
Common Stock Disposition 2014-10-07 2,134 $104.31 9,900 No 4 S Direct
Common Stock Disposition 2014-10-07 400 $105.36 9,500 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-10-07 3,436 $0.00 3,436 $73.51
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
51,564 2024-01-01 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Dr. Chodakewitz's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $103.64 (range $103.03 to $104.01).
  3. Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $104.31 (range $104.03 to $104.92).
  5. Open market sales reported on this line occurred at a weighted average price of $105.36 (range $105.20 to $105.64).
  6. The option vests in 16 quarterly installments from 01/02/2014.